by • August 3, 2016 • No Comments
Nano3D Biosciences has announced a technique to reduce animal testing by via its 3D printed cell cultures and magnetic bioprinting as a test for a drug’s effect on vasoactivity.
The contraction and dilation of blood vessels is a significant area of medicine. If we can control these actions with new compounds and so we can find new ways to manage heart conditions, practuallyt a variety of cardiovascular diseases turning into life threatening conditions and manufacture the future generation of Viagra.
Animal testing is inhumane and inefficient
Today, these compounds are largely tested on animals. That is inhumane, time-consuming, expensive and the subsequent results with human test subjects frequently don’t correlate. So a streamlined test procedure with 3D printed tissue cultures may save time, money and help medical researchers focus their efforts on compounds which in fact work.
Working together with LC Sciences and AstraZeneca, n3D has come up with a cell-based assay process which allows for them to screen cultures rapidly. “It demonstrates the vasoactive effect for a panel of vasodilating and vasoconstricting compounds,” said Hubert Tseng, the Senior R&D Scientist and lead author on the study which was published in Scientific Reports. “We validated this assay with bioprinted animal and human cells, and by doing so, we have an alternative to animal testing to screen vasoactivity.”
n3D President and CSO Dr. Glauco Souza added: “The speed and throughput of our vasoactivity assay sets us apart of other 3D cell culturing and 3D bioprinting techniques, such as the ones of Insphero and Organovo. We are appearing forward to this assay becoming the standard in compound toxicity testing and in the createment of new vasoactive drugs.”
Farming the technique out to big pharma
The Texas-based company can now appear to market the technique to Contract Research Organisations and pharmaceutical companies which want to create cardiovascular drugs.
“This assay is the just one of its kind on the market which can replace animal testing for vasoactivity studies. This assay not just addresses an unmet require in this space, but in addition highlights our versatility and advancement of n3D’s magnetic 3D bioprinting technology,” said n3D Director of Sales & Marketing Carl Froberg. “Speed and throughput can greatly help in controlling cost and allowing advantageous screening of drug candidates earlier in the drug discovery pipeline.”
Animal testing is a controversial subject in the modern age and anything we can do to reduce the amount of drugs tested on them has to be a great thing. As well as the fact which most of the tests just cannot be replicated with human testing, the regulations regarding animal care and testing mean which it is additional expensive than at any time.
Animals require proper care
An animal has to be kept in reasonable conditions and there are just so most tests you can run at a time. Printed cell cultures just require to be stored correctly and the R&D teams can run continuous tests on fresh cultures. That may speed up drug createment.
So there is the greatcan factor. The general public just does not approve of animal testing in the modern age, it’s a controversial subject and if the R&D companies may avoid it altogether it may be a win-win.
Medical testing is set to be serious business for 3D printing
3D printing is an integral part of medical createment may already and it is set to become actually additional significant in the years ahead. A new study suggested which medical 3D printing may generate $3.89 billion a year by 2022.
Whilst 3D printed prosthetics and implants may grab the headlines, printed cell cultures for rapid drug createment may prove to be actually additional significant in the long run.
by admin • March 5, 2017
by admin • November 28, 2016
by admin • November 28, 2016